One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT

Journal of Nuclear Medicine

Volumn 40, Issue 5, 1999, Pages 753-761

  Booij, Jan ^a   Hemelaar, Jos T G M ^b   Speelman, Johannes D ^b   De Bruin, Kora ^b   Janssen, Anton G M ^b   Van Royen, Eric A ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

123I FPCIT; Dopamine transporter imaging; Parkinson's disease; SPECT

Indexed keywords

AMANTADINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE; TRACER;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE TIME EFFECT RELATION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

BRAIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NORTROPANES; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0032902646     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci. 1973;20:415-455.
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med. 1988;876: 876-880.
3. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
4. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231-237.
5. 123I]FP-CIT SPECT shows a pronounced decline of striatal labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.
6. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology. 1997;48:1578-1583.
7. Vingerhoets FJG, Snow BJ, Lee S, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomography studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994;36:759-764.
8. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991;9:43-49.
9. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990;47:1290-1298.
10. 123I]β-CIT. Binding kinetics in the human brain. J Neurol Transm Gen Sect. 1993;94:137-146.
11. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
12. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589-598.
13. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med. 1997;24:68-71.
14. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem. 1994;37:1558-1561.
15. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med. 1996;37:1129-1133.
16. Scheffel U, Lever JR, Abraham P, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse. 1997;25:345-349.
17. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse. 1997;27:183-190.
18. 11C]β-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997;24:621-627.
19. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37:1760-1765.
20. 123I]β-CIT-FP. Parkinsonism Related Disord. 1997;3:77-81.
21. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
22. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med. 1995;36:1175-1181.
23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
24. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7:2-13.
25. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25:24-30.
26. Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med. 1995;22:356-360.
27. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
28. Asenbaum S, Brücke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med. 1997;38:1-6.
29. Malison RT, Laruelle M, Innis RB. Positron and single photon emission tomography. Principles and application in psychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:865-879.
30. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258-261.
31. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982-994.
32. 123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons. Nucl Med Biol. 1995;22:211-219.
33. Seibyl J, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39:1500-1508.
34. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998;39:1143-1148.
35. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993;13:295-309.
36. Moody CA, Granneman JG, Bannon MJ. Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels. Neurosci Lett. 1996;217:55-57.
37. 3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedeberg Arch Pharmacol. 1985;329:227-235.
38. Fang J, Yu PH. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology. 1994;33: 763-768.
39. Wiener HL, Hashim A, Lajtha A, Sershen H. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol. 1989;163:191-194.
40. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294:577-583.